Head-to-head · WeighScore
Claya vs LunaRx
The verdict
Claya takes it — 62.8/100 to 61.2/100, but only just.
Claya grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Claya is a direct-to-consumer telehealth platform offering compounded semaglutide and tirzepatide in both injectable and oral-tablet forms — a wider format range than most competitors. LunaRx is close behind and may still be the better fit — see the factor split below.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Claya | LunaRx |
|---|---|---|
| WeighScore | 62.8/100 | 61.2/100 |
| Grade | C | C |
| Scorecard rank | #267 | #301 |
| Semaglutide | $299/mo (compounded) | $199/mo (starting dose, compounded) |
| Tirzepatide | $299/mo (compounded) | Not disclosed |
| Coverage | Coverage not published | Coverage not published |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Yes | Injection only |
Graded #267 · C
Strengths
- Two named licensed clinicians (Habashy, NMD MS and Barber, MD PhD) — rare transparency for compounded GLP-1
- Two named pharmacy partners with full addresses (RedRock, UT and Healthware, KY)
- Both injectable and oral-tablet forms offered for semaglutide and tirzepatide
- Weight-loss money-back guarantee published on the homepage
- Free expedited shipping included in the monthly price
Where it loses points
- States-served list not disclosed — you must check at checkout
- LegitScript certification status not displayed
- Corporate legal entity not disclosed on the site or privacy policy
- Oral compounded tablets have weaker efficacy data than injectable semaglutide
- Intro pricing is higher at refill ($299), erasing the first-month advantage
Graded #301 · C
Strengths
- Pairs GLP-1 with muscle-protective peptides (e.g., CJC-1295/Ipamorelin, NAD+) to defend lean mass during fat loss
- Structured, physician-directed off-ramp taper with GI-reset support instead of an indefinite prescription
- Bilingual care in English and Spanish across intake, messaging, and consults
- Care directed through a named independent medical group (CareNexus Clinic PC); $0 charged if you are not approved
- Published clinical support hours (Mon–Fri, CT) with phone, email, and secure messaging; cancel anytime
Where it loses points
- Only a "from $199/mo" starting price is published; tirzepatide and per-tier pricing are confirmed only after a provider review
- Compounding pharmacy partners are not named on the site — a transparency gap
- No LegitScript or PCAB verification is displayed
- States served are not published; the site claims "telehealth nationwide" but the Terms limit service to states where LunaRx is licensed
- Compounded medications are not FDA-approved (the site discloses this)
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.